Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

Abstract

In conclusion, rifaximin may be considered for treatment of mild-to-moderate C. difficile infection that is resistant to metronidazole. Larger randomized trials are needed to confirm these positive findings.